43 results about "Porcine influenza" patented technology

The invention relates to a method for preparing a genetic engineering product, in particular to a prokaryotic expression protein of VP73 gene from African swine fever virus (ASFV) and a preparation method thereof. The preparation method comprises: artificially synthesizing the whole-length sequence of VP73 gene according to the sequence of the VP73 gene from ASFV in GenBank, constructing a recombinant expression vector pET32a-VP73, sequencing, verifying, transforming prokaryotic expression recipient bacteria E.coli BL21(DE3), and inducing expression by isopropyl-1-thio-beta-d-galactopyranoside (IPTG), wherein the molecular weight of the recombinant fusion protein is about 65KD. Protein purified by nickel column affinity chromatography can undergo a specific immune imprinting reaction with ASFV positive serum and avoid cross reaction with viruses such as swine fever virus, hog cholera virus, porcine circovirus, porcine reproductive and respiratory syndrome virus, swine influenza virus and pseudorabiesvirus. Experiments show the expressed protein has high detection sensitivity, and high specificity. When the antigen is used for detection, risk of spreading poison is avoided. And the antigen can be used as a detection antigen for use in an enzyme-linked immuno sorbent assay (ELISA) method for identifying an ASFV antibody.

The invention discloses an H1N1 subtype swine influenza virus A / Swine / Shanxi / D5 / 2011 (H1N1) with the preservation number of CGMCC No.5323 and also discloses a vaccine containing the virus. The H1N1 subtype swine influenza virus provided by the invention is not polluted by extraneous pathogeny, has higher multiplication capacity on both a chicken embryo and a cell, shows obvious clinical symptoms after infecting a BALB / c rat and a swine influenza negative piglet and has typical autopsy pathological changes and good immunogenicity, and an oil emulsion inactivated vaccine prepared by using the H1N1 subtype swine influenza virus has 100% of protective efficiency for the attack of a homologous virus after immunizing a pig and serves as a favorable candidate swine influenza vaccine strain.

The invention relates to a vaccine strain of HIN1 swine influenza virus, wherein a classification naming is Swine influenza virus A / Swine / Nanjing / 50 / 2011 (H1N1), and a microbial accession number is CCTCCNO: V201218. According to the invention, isolation, identification and whole genome sequencing of the HIN1 swine influenza virus strain are carried out, and an inactivated vaccine against the swine flu is prepared by using the HIN1 swine influenza virus strain. The inactivated vaccine against the H1NI swine flu prepared from the virus strain can provide good protection for pigs attacked by homologous virulent strains, has good immunogenicity, and can effectively prevent H1NI swine flu with single vaccine or combined vaccines.

The invention belongs to the field of microbial virology and provides a swine influenza A H1N1 virus. The virus contains eight fragments, namely HA, NA, NP, PB1, PB2, PA, NS and M, wherein the nucleotide sequences of the eight fragments are shown by the sequences from No.1 to No.8 in a nucleotide sequence table in the description in turn. In the invention, by separate culture of a nasopharyngeal swab sample of a healthy pig, differential item functioning (DIF) and reverse transcription-polymerase chain reaction (RT-PCR) identification and the comparison of full sequences of 8 genes of the virus, a virus is obtained and verified to be a swine influenza A H1N1 virus strain. The swine influenza A H1N1 virus strain is named A / swine / Zhejiang / 26 / 2009(H1N1), with a collection number of CCTCC No.V201016. The strain obtained by the invention supplies valuable genetic information of swine influenza A virus in China, has a great significance for completing a system for monitoring the infection caused by the pathogen and can be used for preparing a reagent for quickly diagnosing infection with the influenza A H1N1 virus.

Recombinant, chimeric porcine influenza viruses are disclosed that include hemagglutinin segments from more than one influenza virus subtype. Also described are methods of producing the recombinant influenza viruses, immunogenic compositions comprising the recombinant influenza viruses, methods of stimulating an immune response against influenza virus, and methods of treating and preventing influenza virus infection.

The invention discloses a method for determining titer of a swine flu inactivated vaccine. The method comprises the following steps: immunizing a pig with a swine flue inactivated vaccine, collecting blood 21-28 days after immunization and separating blood serum; removing non-specific components in the serum to obtain a serum to be tested; diluting the swine flue inactivated antigen, and preparing a unit swine flue antigen diluent with a concentration of 4HA; and diluting the serum to be tested by multiple proportions, successively adding the 4HA unit swine flue antigen diluent and 1% red cells to conduct hemagglutination inhibition test, so as to completely inhibit highest dilution of the 4HA unit swine flu antigen serum at HI titer. The method has advantages of greatly shortened measurement time, little operation error, strong controllability, and small inter-batch difference, and also reduces detection errors caused by different levels of experimental animals in an animal challenge protection experiment for testing the titer.

The invention relates to veterinary compound hydrochloric acid injection and a preparation method thereof. The veterinary compound hydrochloric acid injection consists of oxytetracycline dihydrate injection, imidocarb and diclofenac sodium; the veterinary compound hydrochloric acid injection per 100 ml comprises the required raw materials of: 10-25g of oxytetracycline dihydrate injection, 1.5-5g of diclofenac sodium, 0.1-0.2g of imidocarb, 0.2-0.6g of sodium formaldehyde sulphoxylate, 5-15g of magnesium chloride, 5-13 ml of ethanolamine and 60-81 ml of organic solvents, wherein the allowance is water for injection. The veterinary compound hydrochloric acid injection has remarkable effect when being used for treating acute respiratory infection caused by eperythrozoon suis, babesiosis and other blood protozoa diseases, porcine respiratory disease complex (PRDC) and swine influenza virus (SIV), airway inflammation induced by porcine reproductive and respiratory syndrome (PRRS), haemophilus parasuis, pasteurella, pleuropneumonia and mycoplasma diseases; and the preparation method is simple and easy to operate, and is suitable for batch production.

The present invention relates to Equine Herpes Virus (EHV) vectors comprising at least one exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, wherein said exogenous antigen encoding sequence is inserted into an insertion site, preferably ORF70, and said exogenous antigen encoding sequence is operably linked to a promoter sequence, preferably the promoter sequence comprising 4pgG600 (SEQ ID NO:1) or 4pMCP600 (SEQ ID NO:2) or the complementary nucleotide sequences thereof or a functional fragment or a functional derivative thereof or the complementary nucleotide sequences thereof. Furthermore, the present invention relates to methods for immunizing a food producing animal comprising administering to such food producing animal an immunogenic composition comprising embodiments of the present invention. Moreover, the present invention relates to methods for the treatment or prophylaxis of clinical signs caused by swine influenza virus in a food producing animal.

The invention relates to universal influenza vaccine and a preparation method thereof. After an influenza virus HA is subjected to gene transfection to eukaryocyte, influenza haemagglutinin (HA) protein subjected to eukaryotic expression modification is inserted into a host plasma membrane, then vesicles largely displaying influenza virus envelope glycoprotein is produced with a method that a surface active agent induces a cell to bud, and the vesicles are changed into controllable and nanometer mimicry virus vesicles with uniform dimensions after purification and re-adding of the surface active agent for treatment. At the same time, by the aid of establishment of stably expressing an HA cell strain and usage of a bioreactor, the method is also applicable to large scale influenza vaccine production. The method is simple and feasible, hemagglutinin of most influenza virus (including avian influenza and swine influenza) can be displayed, and the method has excellent universality, has a great potential and can be used for designing emerging highly lethal influenza virus vaccines.

The invention discloses a nucleic-acid sequence-based amplification (NASBA) method for detecting a swine influenza virus (SIV). The NASBA method mainly comprises the following steps of: extracting the ribonucleic acid (RNA) from the SIV, preparing an NASBA system, preparing an NASBA program, carrying out identification on an NASBA product and carrying out PCR (Polymerase Chain Reaction) amplification. According to the NASBA method, the NASBA rapid detection method is established by taking the NP gene of the SIV as a target gene and is used for the diagnosis of the SIV. The method has higher specificity and sensitivity so as to detect a virus solution with the dilution factor of 10<-5>, so that the method can be used for the rapid detection of clinically-suspected SIV samples, meanwhile, the technical level of China in the diagnosis, epidemic surveillance, inspection and quarantine of swine influenza can be improved so as to ensure the healthful and rapid development of swine industry.

The invention relates to an anti-porcine pseudorabies (PRV) and swine flu (SIV) vaccine composition. Besides porcine pseudorabies and swine flu, the composition can additionally prevent clinical manifestations of porcine respiratory disease complex (PRDC) caused by infection of other pathogenic causes. Furthermore, the invention provides application of the vaccine composition for preparing a medicine in preventing and / or controlling immunized pig PRDC disease. The composition not only avoids interference between antigens in a process of using but also achieves a surprising preventive effect on the porcine respiratory disease complex. Therefore, the vaccine composition disclosed by the invention can simplify an immune procedure and achieve an effect of preventing two diseases by one dosage. The anti-porcine pseudorabies and swine flu vaccine composition, after immunizing pigs, can effectively prevent spread of the PRDC.

The invention provides a mixed virus-like particles, containing stromatin M1 of influenza virus, surface antigen erythrohemagglutinin HA of influenza virus and a nexus protein containing main antigenic epitope contained capsid protein of foot and mouth disease virus and a transmembrane zone and an inner membrane zone of the erythrohemagglutinin HA of influenza virus. The main antigenic epitope contained capsid protein of foot and mouth disease virus substitutes a basically same length outer membrane zone of a 5' terminal of the erythrohemagglutinin HA of influenza virus. Surface antigen erythrohemagglutinin HA of influenza virus and the main antigenic epitope contained capsid protein of foot and mouth disease virus are expressed simultaneously on surfaces of the mixed virus-like particles. The invention also provides a divalent vaccine of swine influenza and foot and mouth disease; and the vaccine contains the mixed virus-like particles and adjuvants. The invention also provides a method for preparing the mixed virus-like particles.

Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.

The invention discloses an amino acid nano-silver liquid as well as a preparation method and an application thereof in disease-free safe raising of pigs. The amino acid nano-silver liquid is prepared by mainly compounding silver sulfate, a cosolvent, an amino acid primary ligand, an amino hetero-ligand, a dispersing agent, a thickening agent, a complexing stabilizer, a pH conditioning agent and deionized water. The amino acid nano-silver liquid has the advantages of having a broad spectrum, high-efficiency and a bactericidal effect, being safe and reliable, being capable of being used for preparation of sterile pig feeds, preventing from serious diseases such as swine influenza and swine fever and disinfecting environments, and being beneficial to realization of the disease-free safe raising of the pigs.

The invention belongs to the field of veterinary vaccines, particularly relates to a quad inactivated vaccine of PCV2-type baculovirus, swine mycoplasma hyopneumoniae, a porcine influenza virus and haemophilus parasuis and further discloses a preparation method for the quad inactivated vaccine and application of the quad inactivated vaccine. The quad inactivated vaccine disclosed by the inventioncontains inactivated protein Cap expressed by the PCV2-type baculovirus, inactivated swine mycoplasma hyopneumoniae, an inactivated porcine influenza virus H1N1subtype virus, inactivated haemophilus parasuis types 4, 5 and 13 and an adjuvant of the vaccine; four kinds of antigens are free of interference to one another, four kinds of protection can be achieved by one injection, and four kinds of epidemic diseases can be prevented through one-time immunization; and meanwhile, in view of toxic substance counteracting protection and serum antibody level, the immunization effect reaches or exceedsthat of each single commodity vaccine, the immunization duration is long, the efficacy is durable, and the quad inactivated vaccine has the advantages that the safety is good, the preparation methodis simple, the immunization is convenient, the immunization cost is reduced, and the like.

The invention provides a shRNA transgenic recombinant plasmid for inhibiting swine influenza viruses. The plasmid contains four shRNA expression genes for simultaneously coding four specific shRNAs capable of respectively targeting influenza virus Pa, PB1, PB2 and NP gene conserved regions. The plasmid is suitable for a plurality of transgenic technologies. After the plasmid is transferred into a MDCK cell cultivated in vitro by a lentivirus carrier, a challenge assay proves that the screened transgenic cell line has a function of resisting infection caused by different subtypes of influenza viruses. The plasmid is injected into a pigling with 4 week old by intravenous injection and intramuscular injection and then the pigling is infected by H3N2 subtype of pig influenza viruses, and the test result shows that an influenza virus replication inhibition function of the blood injection group is better. RNAi is used for pig influenza virus research and pig influenza prevention and treatment so that necessary experiment data is accumulated and thus a base is established for researching influenza resistance of a transgenic pig.

The invention relates to a vaccine composition for preventing and / or treating porcine circovirus diseases and swine influenza and its preparation method and use. The vaccine composition comprises i, a porcine circovirus subunit antigen or a nucleic acid which is used for coding the porcine circovirus subunit antigen and can be expressed in a pig, and ii, a swine influenza virus subunit antigen or a nucleic acid which is used for coding the swine influenza virus subunit antigen and can be expressed in a pig. The invention also relates to a nucleic acid molecule, a recombinant plasmid and a host cell for treating and / or preventing two types of pig diseases.

A permeable material that allows air to easily pass through the interstices in any direction. The permeable material may be a cloth, a mesh, latex, rubber, or any polymer. The material is saturated with a water and / or alcohol based solution containing either a cationic or anionic agent, a disinfecting agent, and a biocide. The solvent on the permeable material is permitted to evaporate. What remains on the permeable material is the cationic or anionic agent and the biocide. This coated material is now surrounded by an electrostatic field. The electrostatically charged material attracts oppositely charged particles and repels similarly charged particles. The particles that contain living organisms are inactivated by the biocide. The formulations have been shown to have efficacy against rhinovirus causing colds, influenza and corona viruses causing diseases such as swine flu and COVID-19, as well as other harmful airborne microscopic and sub-microscopic particles. The material may be formed into products such as face masks, unitary filters, and filtration devices. Users of these masks might want to periodically spray or otherwise apply the solution to the mask to restore its disinfecting, filtration, and biocidic properties. This would also render normally disposable cloth or surgical face masks reusable.

The invention belongs to the field of biotechnology and relates to a novel separated strain swine influenza virus. The invention discloses two separated H9N2 swine influenza viruses. According to the invention, it firstly proves that the two strains both belong to Ck / Bei series. The invention also discloses a kit for detecting the H9N2 swine influenza viruses. Through the kit provided by the invention, whether swine flu is caused by the genotype of H9N2 swine influenza viruses can be rapidly detected or eliminated so as to control the swine flu epidemic situation as soon as possible. In addition, by the use of the kit, bioinformation for a swine influenza virus monitoring system can be provided.

The invention discloses a pathogenic bacteria killing and environment control breeding house applied to an epidemic prevention of swine influenza. The pathogenic bacteria killing and environment control breeding house comprises a breeding house body, shutter bodies and a device box, a house door is hinged and fixed to an outer side of the breeding house body, positioning columns are welded and fixed to a top part of the breeding house body, outer sides of the shutter bodies are connected with the breeding house body in an embedded mode, flexible solar panels are bonded and fixed to the outer side of the breeding house body, a waste collecting box is welded and fixed to a bottom plate of the breeding house, chassis supporting piles are welded and fixed to two sides of the waste collecting box, and pollution discharge pipelines are welded and fixed to a bottom plate of the waste collecting box. The pathogenic bacteria killing and environment control breeding house applied to an epidemicprevention of swine influenza is provided with first eccentric wheels and bevel gears, the first eccentric wheels are used for driving spraying supports to move left and right, a moving range betweenthe spraying supports is adjusted according to a width of the breeding house, and an interior of the breeding house can be conveniently and automatically sterilized.

This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof.

A provided vaccine composition for preventing and treating porcine respiratory syndrome comprises immunization amount of porcine influenza virus antigen, immunization amount of porcine pneumonia mycoplasma antigen, immunization amount of haemophilus parasuis antigen, and an adjuvant. The vaccine composition is capable of effectively preventing and controlling porcine respiratory syndrome caused by mixed infection of the three kinds of pathogeny, and also is capable of reducing vaccine inoculating frequency and avoiding unavailable full-access immunization caused by missed inoculation.

The invention discloses a method for determining titer of a swine flu inactivated vaccine. The method comprises the following steps: immunizing a pig with a swine flue inactivated vaccine, collecting blood 21-28 days after immunization and separating blood serum; removing non-specific components in the serum to obtain a serum to be tested; diluting the swine flue inactivated antigen, and preparing a unit swine flue antigen diluent with a concentration of 4HA; and diluting the serum to be tested by multiple proportions, successively adding the 4HA unit swine flue antigen diluent and 1% red cells to conduct hemagglutination inhibition test, so as to completely inhibit highest dilution of the 4HA unit swine flu antigen serum at HI titer. The method has advantages of greatly shortened measurement time, little operation error, strong controllability, and small inter-batch difference, and also reduces detection errors caused by different levels of experimental animals in an animal challenge protection experiment for testing the titer.